Bollard Group’s Blueprint Medicines BPMC Stock Holding History

Bollard Group’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,000	Closed	-$1.12M	–	432
2020 Q4	$1.12M	Hold	10,000	–	–	0.04%	114
2020 Q3	$927K	Hold	10,000	–	–	0.03%	122
2020 Q2	$780K	Hold	10,000	–	–	0.03%	119
2020 Q1	$585K	Hold	10,000	–	–	0.03%	115
2019 Q4	$801K	Hold	10,000	–	–	0.03%	121
2019 Q3	$735K	Buy	+10,000	New	+$864K	0.03%	124
2019 Q2	–	Sell	-47,300	Closed	-$3.79M	–	250
2019 Q1	$3.79M	Hold	47,300	–	–	0.14%	83
2018 Q4	$2.55M	Buy	47,300 +1,800	+4%	+$109K	0.11%	89
2018 Q3	$3.55M	Sell	45,500 -7,500	-14%	-$521K	0.14%	80
2018 Q2	$3.36M	Buy	53,000 +14,750	+39%	+$1.17M	0.15%	73
2018 Q1	$3.51M	Buy	+38,250	New	+$3.3M	0.17%	71

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bollard Group's BPMC Position: Q1 2021 in Review

Bollard Group sold out of Blueprint Medicines (BPMC) in Q1 2021, closing a stake of 10,000 shares — an estimated $1.12M sold.

Bollard Group first reported a position in BPMC in Q1 2018 and held it in 11 quarters. The position peaked at $3.79M in Q1 2019. 264 funds tracked by Wall St. Rank hold BPMC as of Q1 2021.

Bollard Group reported no remaining Blueprint Medicines position as of Q1 2021 after selling out during the quarter.
Bollard Group sold 10,000 Blueprint Medicines shares in Q1 2021, an estimated $1.12M.
Bollard Group first reported a position in Blueprint Medicines in Q1 2018 and held it in 11 quarters.
Bollard Group's Blueprint Medicines position peaked at $3.79M in Q1 2019.
264 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2021.

Based on Bollard Group's 13F filing for Q1 2021, filed 11 May 2021.